Dr. Schnabel Discusses the DCIS Recurrence Score

Video

Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score

Freya R. Schnabel, MD, Professor of Surgery, NYU School of Medicine, discusses ability to predict the risk for recurrence in women with ductal carcinoma in situ (DCIS) using a new 12-gene assay named the DCIS Score.

The study that examined the DCIS Score was designed to explore the tumor samples of women who had received surgery alone without radiation. This analysis found a panel of genes that could help predict whether the patient was at low-, intermediate-, or high-risk for recurrence.

Determining the recurrence risk at the time of lumpectomy aids future treatment decisions, including whether or not to use radiation therapy. Schnabel labels the ability to predict risk a major advance.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD